Genvor Incorporated Files Q1 2026 Financial Report Amendment: Key Details for Investors

Overview

Genvor Incorporated has filed Amendment No. 1 to its Quarterly Report on Form 10-Q/A for the period ended December 31, 2025. The amendment is intended to correct two typographical checkbox errors on the cover page of the original filing, submitted on February 12, 2026. It is important to note that this amendment does not update any events that may have occurred after the original filing date, nor does it modify or update any other disclosures or forward-looking statements, except for the error correction and updated certification exhibits. Investors should read this amendment alongside the original quarterly report.

Key Financial Highlights

• Net Loss: For the three months ended December 31, 2025, Genvor reported a net loss of \$576,280. This compares to a significantly larger net loss of \$5,001,251 for the same period in 2024, indicating a substantial improvement in the company’s financial performance.
• Stockholders’ Deficit: The total stockholders’ deficit as of December 31, 2025 was \$1,059,320, reduced from \$1,312,382 as of September 30, 2025. This reduction signals positive progress in managing company deficits.
• Common Shares Outstanding: As of February 11, 2026, Genvor had 34,938,000 shares of common stock outstanding.
• Basic and Diluted Net Loss Per Share: Net loss per common share for Q1 2026 was reported at \$0.02, compared to \$0.24 in Q1 2025, further highlighting improved financial health.
• Weighted Average Shares Outstanding: The weighted average number of common shares outstanding during Q1 2026 was 32,762,434, up from 20,665,478 in Q1 2025, indicating active share issuance and possibly capital raising activities.

Capital and Shareholder Transactions

• Common Stock Issuance: During the quarter, Genvor issued common stock for various purposes:
  • Conversion of Series B Preferred Stock: 150,000 shares issued.
  • Cash: 520,000 shares issued for cash, raising \$520.
  • Accrued Services: 505,000 shares issued; \$505 attributed to share value, \$125,745 to additional paid-in capital.
  • Compensation: 250,000 shares issued; \$250 attributed to share value, \$124,750 to additional paid-in capital.
  • Conversion of Note Payable & Accrued Interest: 22,092 shares issued; \$22 attributed to share value, \$22,070 to additional paid-in capital.
• Preferred Stock:
  • Series A: 10 shares authorized, 6 shares outstanding at both quarter ends.
  • Series B: 1,910,536 shares issued, 1,405,024 shares outstanding as of December 31, 2025; 502,512 shares held in treasury at cost (\$300,000).
  • Value of Series B Preferred Stock: \$1,910 as of December 31, 2025, decreased from \$2,061 as of September 30, 2025.
• Treasury Stock: 502,512 Series B preferred shares held in treasury at both reporting dates.

Liquidity and Going Concern

Genvor highlights ongoing liquidity risk and the company’s dependence on capital raising. Management intends to raise additional funds through public or private offerings of stock to support daily operations and further development of products and technologies. The company asserts belief in its strategy to generate revenues and raise funds but acknowledges that there are no assurances these efforts will succeed. The ability to continue as a going concern depends on successful execution of the business plan and generation of cash flows from financing or operations.

Shareholder and Market Sensitivities

• Improved Financial Results: The substantial reduction in net loss year-on-year and narrowing of stockholders’ deficit may be viewed positively by investors and could impact share price.
• Active Capital Raising: Issuance of millions of shares during the quarter for various purposes, including conversions, compensation, and cash raises, may dilute existing holdings but also provides needed capital. The increase in shares outstanding and paid-in capital is notable.
• Liquidity Concerns: The explicit disclosure of liquidity risk and dependence on future capital raises is a critical issue for shareholders and could affect valuation or investor confidence.
• Correction of Filing Errors: While the amendment itself is not material to financial results, it reflects attention to regulatory compliance and may reassure investors regarding administrative diligence.

Additional Notes

• Company Classification: Genvor is listed as a smaller reporting company and an emerging growth company, which may affect both disclosure requirements and investor perception.
• No Trading Symbols: The company currently lists “N/A” for trading symbols and exchanges, with common stock registered under Section 12(g), \$0.001 par value.
• Non-Cash Activities: The report notes significant non-cash transactions, particularly accrued compensation settled with common stock and conversion of note payable and accrued interest to common stock.

Conclusion

For investors, the most price-sensitive information is:

• The improved financial performance (lower net loss).
• The ongoing liquidity risk and need for future capital raising.
• The issuance of a substantial number of shares, which could impact share dilution.

These factors, combined with the company’s declaration of being a going concern contingent on successful capital raising, should be closely monitored.

Disclaimer: This article is based on Genvor Incorporated’s Q1 2026 Form 10-Q/A and related financial statements. It is intended for informational purposes only and does not constitute financial advice, investment advice, or a recommendation to buy or sell securities. Investors should conduct their own due diligence and consult with professional advisors before making investment decisions. The information is provided as of the date of the report and may be subject to change.

View Genvor Inc Historical chart here